Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alnylam Pharmaceuticals
(NQ:
ALNY
)
143.95
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alnylam Pharmaceuticals
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
July 01, 2022
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.
Via
Benzinga
Where Alnylam Pharmaceuticals Stands With Analysts
June 27, 2022
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022
June 27, 2022
Upgrades
Via
Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
June 07, 2022
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:
Via
Benzinga
Alnylam's Lumasiran Shows Clinical Benefit In Rare Kidney Disease
May 24, 2022
Via
Benzinga
The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate
June 14, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Alnylam's Stock Gains Following FDA Nod For hATTR Amyloidosis Candidate
June 13, 2022
The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ (NASDAQ: ALNY) lead drug candidate AMVUTTRA (Vutrisiran) for the treatment of the polyneuropathy of hereditary...
Via
Benzinga
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
June 13, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline
May 02, 2022
Via
Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
April 12, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:
Via
Benzinga
See Why Did FDA Extend Review Period For Alnylam's Vutrisiran In Amyloidosis
April 04, 2022
Via
Benzinga
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
June 09, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022
June 07, 2022
Upgrades
Via
Benzinga
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
June 02, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic Tissues
June 02, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
May 24, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
May 23, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
May 04, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
10 Biggest Price Target Changes For Monday
May 02, 2022
Morgan Stanley boosted Archer-Daniels-Midland Company (NYSE: ADM) price target from $69 to $94. Archer-Daniels-Midland shares fell 0.5% to $89.10 in pre-market trading.
Via
Benzinga
Expert Ratings for Alnylam Pharmaceuticals
April 29, 2022
Over the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
April 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity
April 28, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
What To Know About Morgan Stanley's Downgrade of Alnylam Pharmaceuticals
April 25, 2022
Morgan Stanley downgraded its rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) to Equal-Weight with a price target of $178.00, changing its price target from $210.00 to $178.00. Shares of Alnylam...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
April 25, 2022
Via
Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
April 24, 2022
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...
Via
Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
April 21, 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.
Via
InvestorPlace
Alnylam Pharmaceuticals Q1 2022 Earnings Conference Call On April 28, 2022 At 08:30 AM ET
April 19, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) will host a conference call at 08:30 AM ET on April 28, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
Alnylam to Webcast Conference Call Discussing First Quarter 2022 Financial Results
April 14, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors
April 05, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
April 04, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.